Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	22.04B
Revenue (ttm)	1.68B
Net Income (ttm)	598.95M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	36.80
Forward PE	34.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	52
Open	3.544
Previous Close	3.544
Day's Range	3.544 - 3.544
52-Week Range	1.880 - 5.580
Beta	0.63
RSI	84.93
Earnings Date	Aug 26, 2025

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2024, HNSPF's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY